Copertina

Reply: Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Zhiyuan Cheng, Jiesheng Lin, Dongfeng Gu, Fengchao Liang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Journal of Diabetes
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
di: Fei Lu
Pubblicazione: (2026)

An Update on GLP‐1 Receptor Agonists
di: Zachary Bloomgarden
Pubblicazione: (2025)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
di: Zhiyuan Cheng, et al.
Pubblicazione: (2024)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
di: Yue Yin, et al.
Pubblicazione: (2025)

Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
di: Tomohiko Kimura, et al.
Pubblicazione: (2024)

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review
di: Jimmy Wen, et al.
Pubblicazione: (2025)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
di: Roberta Scairati, et al.
Pubblicazione: (2026)

Beyond GLP ‐1
di: Zachary Bloomgarden
Pubblicazione: (2026)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
di: Sanbao Chai, et al.
Pubblicazione: (2024)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
di: Matheus Souza, et al.
Pubblicazione: (2026)

Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head‐to‐Head Comparison of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists for Incident Dementia
di: Shio‐Shin Jean, et al.
Pubblicazione: (2026)

Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study
di: Daniel Yuan, et al.
Pubblicazione: (2025)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
di: Inyoung Hwang, et al.
Pubblicazione: (2026)

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
di: A. G. Barajas, et al.
Pubblicazione: (2025)

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
di: Zachary Bloomgarden
Pubblicazione: (2024)

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
di: Lasin Ozbek, et al.
Pubblicazione: (2026)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
di: Cynthia F. X. C. A. Silva, et al.
Pubblicazione: (2026)

HbA1c and the Risk of Lower Limb Ulcers Among Diabetic Patients: An Observational and Genetics Study
di: Guojun Guo, et al.
Pubblicazione: (2025)

Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis
di: Yucheng Yang, et al.
Pubblicazione: (2025)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
di: Jirawan Vienghirun, et al.
Pubblicazione: (2026)

Adverse Liver and Renal Outcomes After Initiating SGLT‐2i and GLP‐1RA Therapy Among Patients With Diabetes and MASLD
di: Arunkumar Krishnan, et al.
Pubblicazione: (2025)

Cardiovascular and kidney benefits of GLP ‐1 receptor agonists across large randomized placebo‐controlled trials
di: Satoshi Yoshiji, et al.
Pubblicazione: (2025)

Commentary on “Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes ( post hoc analysis of RECAP study)”
di: Yu Zhang, et al.
Pubblicazione: (2025)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
di: Rayanne Santos de Paulo, et al.
Pubblicazione: (2026)

Searching the Crystal Ball for Tailored GLP‐1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity
di: Asia Saturnino, et al.
Pubblicazione: (2024)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
di: Mikhail Khachaturov, et al.
Pubblicazione: (2026)

Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
di: Ahmed Y. Azzam, et al.
Pubblicazione: (2025)

Dietary Choline and Betaine Are Not Associated With the Risk of Type 2 Diabetes. A Systematic Review and Meta‐Analysis of Observational Studies
di: Elham Sharifi-Zahabi, et al.
Pubblicazione: (2026)

Identifying Provider Prescribing Practices for GLP‐1RAs and SGLT‐2is in Patients With Type 2 Diabetes to Address Pharmacoinequity
di: Parnnate Wongsirisakul, et al.
Pubblicazione: (2026)

Healthy Sleep Behaviors Reduce the Risk of Microvascular and Cardiovascular Complications in Patients With Type 2 Diabetes and Are Associated With Potential Serum Biomarkers: A UK Biobank Observational Cohort Study
di: Rui Lan, et al.
Pubblicazione: (2025)

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation
di: Haisheng Wu, et al.
Pubblicazione: (2026)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
di: Tahmid Hussain, et al.
Pubblicazione: (2026)

Association Between Diabetes and Site‐Specific Cancer Risk: A Population‐Based Cohort Study on the Differential Role of Metabolic Profiles
di: Sarah Tsz Yui Yau, et al.
Pubblicazione: (2025)

Diabetes Complications and Comorbidities as Risk Factors for MACE in People With Type 2 Diabetes and Their Development Over Time: A Danish Registry‐Based Case–Control Study
di: Asger Ahlmann Bech, et al.
Pubblicazione: (2025)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
di: Yazan Alhamdan, et al.
Pubblicazione: (2026)

First‐Degree Family History of Diabetes Is Associated With the Presence of Depressive Symptoms Independent of Lifestyle Risk Factors and Cardiometabolic Risk Factors
di: Mengying Chen, et al.
Pubblicazione: (2025)

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study
di: Arvid Engström, et al.
Pubblicazione: (2026)

Glucokinase Regulatory Protein as a Putative Target for Gestational Diabetes Mellitus and Related Complications: Evidence From the Mendelian Randomization Study
di: Weian Mao, et al.
Pubblicazione: (2025)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
di: Muhammad Tahir, et al.
Pubblicazione: (2026)

Causal Association Between Commonly Used Medicines and Diabetes‐Related Eye Diseases: Univariable and Multivariable Mendelian Randomization Study
di: Yu Wang, et al.
Pubblicazione: (2026)